Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

Top Cited Papers
Publisher Website
Google Scholar
Abstract
In this Review, Harris and colleagues discuss historical and contemporary approaches to androgen deprivation therapy for patients with prostate cancer. They then focus on mechanisms of castration resistance, and discuss novel targeted therapies for patients with this disease. Androgen deprivation therapy remains a critical component of treatment for men with advanced prostate cancer, and data support its use in metastatic disease and in conjunction with surgery or radiation in specific settings. Alternatives to standard androgen deprivation therapy, such as intermittent androgen suppression and estrogen therapy, hold the potential to improve toxicity profiles while maintaining clinical benefit. Current androgen deprivation strategies seem to incompletely suppress androgen levels and androgen-receptor-mediated effects at the tissue level. Advances in the understanding of mechanisms that contribute to castration-resistant prostate cancer are leading to rationally designed therapies targeting androgen metabolism and the androgen receptor. The results of large trials investigating the optimization of primary androgen deprivation therapy, including evaluation of intermittent androgen suppression and phase III studies of novel androgen synthesis inhibitors, such as abiraterone acetate, are eagerly awaited.

This publication has 72 references indexed in Scilit: